Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Achaogen, Inc.AKAO · Entity 158957 | Director | June 05, 2018 | June 07, 2018 |
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 05, 2026 | June 10, 2026 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Chief Admin Officer & SVP | February 21, 2020 | February 25, 2020 |
| NEOGENOMICS INCNEO · Entity 2096 | Chief Legal Officer | March 01, 2022 | March 04, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Achaogen, Inc.
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.07 · Expires 2028-06-05 | Direct | 15,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Arcutis Biotherapeutics, Inc.
Report date June 05, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,901 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 5,778 · Balance 27,901 F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.23 · Expires 2036-06-05 | Direct | 16,667 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,667 · Balance 16,667 F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
IRONWOOD PHARMACEUTICALS INC
Report date February 21, 2020 · Filed February 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 265,991 |
Ending reported balance
After 2020-02-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-02-21 · Sale · Disposed 2,753 · Balance 278,566 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2020-02-21 · Sale · Disposed 3,410 · Balance 275,156 F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2020-02-21 · Sale · Disposed 2,984 · Balance 272,172 F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2020-02-21 · Sale · Disposed 6,181 · Balance 265,991 F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
NEOGENOMICS INC
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,396 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 42,036 · Balance 147,396 F1: On March 1, 2022, Ms. Gilbert was granted 42,036 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. F2: This balance includes 97 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares were acquired in transactions exempt from Section 16b-3. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2029-03-01 | Direct | 102,623 |
Reported balance
After 2022-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-01 · Grant · Acquired 102,623 · Balance 102,623 F4: On March 1, 2022, Ms. Gilbert was granted 102,623 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.21 · Expires 2028-08-17 | Direct | 63,331 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 63,331 F3: On August 17, 2021, Ms. Gilbert was granted 63,331 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 1, 2022, Ms. Gilbert was granted 42,036 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.
F2: This balance includes 97 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares were acquired in transactions exempt from Section 16b-3.
F3: On August 17, 2021, Ms. Gilbert was granted 63,331 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 1, 2022, Ms. Gilbert was granted 102,623 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,481 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 12,481 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2029-11-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2020 Filed Feb 4, 2020 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 60,000 | $10.02 | $601,200.00 |
DisclosureSEC source: 0001209191-20-006267 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 41,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061132 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,319 F1 · kind: The restricted stock units, granted as a special retention award, vest as to 100% of the shares of Class A Common Stock on November 18, 2021. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 17:46 UTC | Dermira, Inc. DERM · Entity 11896 | GrantStock Options (Right to buy) · Derivative | 20,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001562180-19-005497 · primarydocument.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-11-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/3rd of the shares in equal annual installments with the first 1/3rd of the shares vesting on November 11, 2020, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 20:48 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $4.88 Strike: $4.88 | $97,600.00 |
DisclosureSEC source: 0001209191-19-043685 · doc4.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,472 Underlying: Class A Common Stock · 20,000 shares Expires 2019-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 20,000 shares of Class A Common Stock upon the issuer's achievement of a commercial milestone on January 4, 2017. The remainder of the option expired on July 28, 2019. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 20:48 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 20,000 | $10.00 | $200,000.00 |
DisclosureSEC source: 0001209191-19-043685 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,169 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $10.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 20:48 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 20,000 | $4.88 | $97,600.00 |
DisclosureSEC source: 0001209191-19-043685 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reporting person acquired 1,929 shares of Class A common stock under the issuer's employee stock purchase plan on June 28, 2019. Read SEC document |
| May 10, 2019 Filed May 14, 2019 20:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 4,055 | $10.53 | $42,699.15 |
DisclosureSEC source: 0001209191-19-029605 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,240 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on July 31, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $10.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,472 | Not disclosed Strike: $4.88 | Not disclosed |
DisclosureSEC source: 0001209191-19-023431 · doc4.xml · derivative · entry 6 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,472 Underlying: Class A Common Stock · 2,472 shares Expires 2019-07-28 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F7 · derivative.exercise_date: The option has vested as to 20,000 shares as of the date hereof. The remaining shares will vest upon the issuer's achievement of a certain milestone. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 16,804 | Not disclosed Strike: $11.49 | Not disclosed |
DisclosureSEC source: 0001209191-19-023431 · doc4.xml · derivative · entry 5 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,804 Underlying: Class A Common Stock · 16,804 shares Expires 2029-01-29 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 5,949 | Not disclosed Strike: $12.95 | Not disclosed |
DisclosureSEC source: 0001209191-19-023431 · doc4.xml · derivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,949 Underlying: Class A Common Stock · 5,949 shares Expires 2028-02-21 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,326 | Not disclosed Strike: $14.93 | Not disclosed |
DisclosureSEC source: 0001209191-19-023431 · doc4.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,326 Underlying: Class A Common Stock · 4,326 shares Expires 2027-02-27 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,506 | Not disclosed Strike: $9.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-023431 · doc4.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,506 Underlying: Class A Common Stock · 1,506 shares Expires 2026-03-01 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F3 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2016. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 17,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023431 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,295 F1 · price: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received 17,165 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock units are subject to vesting conditions consistent with the terms of the existing Ironwood restricted stock units held by the reporting person prior to the Separation. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 22 | $14.32 | $315.04 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 8 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,130 F5 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 25 | $14.32 | $358.00 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 7 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,152 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 20 | $14.32 | $286.40 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 6 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,177 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 18 | $14.32 | $257.76 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 5 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,197 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,609 | $14.31 | $37,334.79 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,215 F5 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,982 | $14.31 | $42,672.42 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,824 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,423 | $14.31 | $34,673.13 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,806 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 21:51 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,143 | $14.31 | $30,666.33 |
DisclosureSEC source: 0001209191-19-012643 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,229 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 22:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option(Right to Buy) · Derivative | 20,449 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-19-006228 · doc4.xml · derivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,449 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option fully vested as of January 1, 2013. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 22:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 20,449 | $4.89 | $99,995.61 |
DisclosureSEC source: 0001209191-19-006228 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option(Right to Buy) · Derivative | 145,000 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006228 · doc4.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Class A Common Stock · 145,000 shares Expires 2029-01-29 F2 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 72,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006228 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,923 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001509 · doc4.xml · derivative · entry 7 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2019-07-29 F2 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F5 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 20,000 shares of Class B Common Stock upon the Issuer's achievement of commercial milestones. The option has not vested as to any shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001509 · doc4.xml · derivative · entry 6 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2019-07-29 F2 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F5 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 20,000 shares of Class B Common Stock upon the Issuer's achievement of commercial milestones. The option has not vested as to any shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001509 · doc4.xml · derivative · entry 5 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2019-07-29 F2 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F4 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 20,000 shares of Class B Common Stock upon the Issuer's achievement of certain regulatory milestones. The option has vested as to 20,000 shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001509 · doc4.xml · derivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class B Common Stock · 20,000 shares Expires 2019-07-28 F2 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F4 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 20,000 shares of Class B Common Stock upon the Issuer's achievement of certain regulatory milestones. The option has vested as to 20,000 shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 20,449 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001209191-19-001509 · doc4.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,449 Underlying: Class A Common Stock · 20,449 shares Expires 2019-02-11 F2 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and vested as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option ( Right to Buy) · Derivative | 20,449 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001209191-19-001509 · doc4.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 20,449 shares Expires 2019-02-11 F2 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and vested as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 21:57 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045053 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,899 F1 · kind: The restricted stock unit award, granted as a recognition award, vests as to 100% of the shares of Class A Common Stock on May 9, 2019. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 20:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option(Right to Buy) · Derivative | 29,551 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-18-041567 · doc4.xml · derivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,449 Underlying: Class B Common Stock · 29,551 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and vested as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 20:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 29,551 | $19.75 | $583,632.25 |
DisclosureSEC source: 0001209191-18-041567 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 20:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 29,551 | $4.89 | $144,504.39 |
DisclosureSEC source: 0001209191-18-041567 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 18:52 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001140361-18-027769 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option(Right to Buy) · Derivative | 70,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012579 · doc4.xml · derivative · entry 5 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Class A Common Stock · 70,000 shares Expires 2028-02-21 F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-012579 · doc4.xml · nonDerivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,204 F6 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,987 | $14.66 | $43,789.42 |
DisclosureSEC source: 0001209191-18-012579 · doc4.xml · nonDerivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,204 F5 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,411 | $14.66 | $35,345.26 |
DisclosureSEC source: 0001209191-18-012579 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,191 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,343 | $14.66 | $34,348.38 |
DisclosureSEC source: 0001209191-18-012579 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,602 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The reporting person acquired a total of 1,138 shares of Class A Common Stock under the issuer's employee stock purchase plan in the following transactions: 791 shares acquired on June 30, 2017 and 347 shares acquired on December 31, 2017. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 20:22 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-17-041833 · doc4.xml · derivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 35,000 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested upon the earlier of (i) the issuer's achievement of a commercial milestone and (ii) February 1, 2014. The commercial milestone was met, so the option was fully vested as of December 21, 2012. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 20:22 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 35,000 | $19.75 | $691,250.00 |
DisclosureSEC source: 0001209191-17-041833 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 20:22 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 35,000 | $3.76 | $131,600.00 |
DisclosureSEC source: 0001209191-17-041833 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 18:59 UTC | Achaogen, Inc. AKAO · Entity 158957 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $22.11 | $0.00 |
DisclosureSEC source: 0001140361-17-025422 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual meeting of stockholders to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $16.77 | $0.00 |
DisclosureSEC source: 0001209191-17-016105 · doc4.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Class A Common Stock · 80,000 shares Expires 2027-02-27 F2 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016105 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,807 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,674 | $16.94 | $45,297.56 |
DisclosureSEC source: 0001209191-17-014361 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,807 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.47 to $17.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,365 | $16.94 | $40,063.10 |
DisclosureSEC source: 0001209191-17-014361 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,481 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.47 to $17.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:12 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 37,385 | $3.76 Strike: $3.76 | $140,567.60 |
DisclosureSEC source: 0001209191-17-011203 · doc4.xml · derivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 37,385 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 25% of the shares of Class B Common Stock on the first anniversary of February 1, 2008, and 1/48th of the shares of Class B Common Stock vested each month thereafter for the next 36 months. The option was fully vested as of February 1, 2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.